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Abstract
We have analysed the course of surgery in 146 patients with pacemakers who underwent transurethral resection of 
a prostate or bladder tumour at the Department of Urology in the five years 2014 to 2018 inclusive. In the study group, 
spinal anaesthesia was performed in 48 patients (32.9%) and general anaesthesia in 98 patients (67.1%). The average 
time of surgery was 71.8 minutes. Bipolar electroresections were performed in six patients and unipolar in 140 patients. 
Electrocardiography (ECG) monitoring and pulse oximetry evaluation were used continuously and for up to four hours 
after the procedure, and resting 12-lead ECG was performed before and immediately after surgery. Pacemaker control 
was performed before and after the procedure in the pacemaker control office. No case of significant cardiac pacemaker 
disturbance was observed. Transurethral electroresection of bladder and prostate tumours in patients with implanted 
pacemakers where guidelines and recommendations were adhered to were not associated with the occurrence of 
pacemaker complications.
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Introduction
Both experimental studies and observations collected 
during diathermy procedures in patients with pacemakers 
have suggested that in cases of transurethral prescriptive 
prostate resection (TURP) and transurethral resection of 
bladder tumours (TURBT) disturbed pacemaker functioning 
may occur and is associated with a subsequent slowdown 
of heart function, arrhythmia, asystole, and even ventricular 
fibrillation [1–8]. For this reason, patients with pacemakers 
require adequate preparation before, during and after 
surgery, as well as adherence to peri-operative procedures 
to prevent undesirable complications [9, 10].
The aim of this study was to analyse 146 patients with 
pacemakers undergoing endoscopic procedures who were 
treated at the Urology Department in 2014–2018 to assess 
the safety of treatment in this group of patients.
Materials and methods
Between 2014 and 2018, transurethral procedures (TURP 
and TURBT) were performed in 2,787 patients in the 
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Electrocardiography (ECG) monitoring and pulse oxi-
metry evaluation were used continuously during the 
procedures and for up to four hours after the procedure. 
12-lead resting ECG was routinely performed before and 
immediately after the procedure. Each patient was monito-
red for pacemaker function before and after the procedure 
in the pacing room.
Transurethral electroresection procedures for both blad-
der tumours (TURBT) and prostate (TURP) were performed 
as unipolar or bipolar procedures (in saline).
TURBT (bladder tumour removal) procedures were 
generally performed using unipolar electrocoagulation. 
The loop of the resectoscope inserted into the urethra was 
the active electrode, and the passive electrode plate was 
glued to the patient’s thigh or buttock. There was a cur-
rent flow between electrodes, and the highest impedance 
occurred on the active electrode, which resulted in a rise 
in temperature enabling tissue separation or coagulation. 
Unipolar electroresection procedures were performed in 
non-electrolyte solutions so that the current flowed through 
the patient’s tissues between the active electrode (the loop) 
and the passive one (the plate).
During bipolar electroresection, mainly used for pro-
state adenomas resection, current flow occurred between 
two elements of the loop, or between the loop and the tip 
of the resectoscope jacket, causing evaporation of the 
solution and the formation of a high-temperature plasma 
Urology Department (652 women and 2,135 men). The 
mean age of patients was 71 years (Table 1).
The 146 TURP and TURBT procedures in patients with 
implanted cardiac pacemakers were analysed. This repre-
sented 5.23% of all transurethral resections performed at 
the Department during that time (Tables 2, 3).
Anaesthesia used
Regional, subarachnoid anaesthesia is the gold standard 
anaesthetic management for this type of procedure. If 
there is a contraindication for subarachnoid anaesthesia, 
general anaesthesia is used.
Subarachnoid anaesthesia was per formed in 
1,927 (69.15%) and general anaesthesia in 860 (30.85%) 
patients. In the study group, subarachnoid anaesthesia was 
performed in 48 patients (32.9%), and general anaesthesia 
in 98 patients (67.1%); details are presented in Table 2.
Table 1. Demographics of patients undergoing transurethral surgery
Total transurethral procedures 2014–2018 (five years) 2,787 Percentage (%)
TURP 578 20.7
TURBT 2,209 79.3
Women 652 23.4
Men 2,135 76.6
Patients with pacemakers (total) 146 5.23
Subarachnoid anaesthesia 1,927 69.15
General anaesthesia 860 30.85
Average age of patients (years) 71
TURP — transurethral prescriptive prostate resection; TURBT — transurethral resection of bladder tumours
Table 2. Demographics of patients with pacemakers undergoing transurethral surgery
Total number of pacemakers 146 Percentage (%)
Women 35 23.97
Men 111 76.03
Subarachnoid anaesthesia 48 32.9
General anaesthesia 98 67.1
Average age of patients (years) 71.42
Average duration of treatment (minutes) 71.8
Table 3. Types of cardiac pacing for patients undergoing transu-
rethral procedures
Stimulation type Percentage of patients (%)
VVI 13.85
AAI 18.46
DDDR 67.69
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in which a constant current flow occurred. The temperature 
generated during cutting was lower than during traditional 
resection, resulting in less thermal damage to surrounding 
tissues. By using saline as a flushing fluid, the risk of 
a post-resection syndrome (TUR syndrome) was practically 
eliminated.
Results
In the studied group of patients with pacemakers, the ma-
jority (67.1%) were operated under general anaesthesia, 
while in 32.9% subarachnoid anaesthesia was used. The 
average duration of the procedure was 71.8 minutes. The 
number of treatments in individual years is shown in Tab-
le 4. Details of the treatments are given in Tables 4 and 5.
Only in four cases was the pacemaker deactivated with 
a magnet being used during the operation.
No patient had a cardiac pacing disorder. In the outpa-
tient control of patients after surgery, there was no case of 
damage to the pacing system.
Discussion
The spectacular progress in cardiology observed since the 
mid-twentieth century, and the significant extension of life 
in people with cardiovascular diseases, have resulted in 
a large increase in the number of patients with implanted 
cardiac stimulation systems.
The cardiac pacing system consists of a battery-
-containing pacemaker, a system that analyses the heart 
rhythm, a system that activates stimulation when necessa-
ry, a system that generates electrical impulses, and elec-
trodes that connect the pacemaker to the heart muscle.
Currently, both single and dual cavity pacemakers are 
used for permanent cardiac pacing. The site of stimulation 
is usually the right ventricle and right atrium. Stimulants 
are marked with a letter code. These letters mean:
 — pacing site (A — atrium, V — ventricle, D — both cavities);
 — potential reading location (A, V, D);
 — pacemaker response method (I — braking, T — trig-
gering, D — both types)
 — the ability to adapt the stimulation rate to exercise 
(O — none, R — rhythm modification)
In clinical practice, two-chamber stimulation types are 
most commonly used: AAI (R), VVI (R), VDD, DDD (R), and 
two-chamber stimulation (CRT, cardiac resynchronisation 
therapy) that involves synchronous stimulation of the right 
and left ventricles.
With VVI pacing (right ventricle electrode, ventricular 
control and pacing), there is a lack of synchronisation 
Table 4. Data on transurethral resection of the prostate (TURP) broken down by year
Year TURP Pacemaker Unipolar Bipolar Time
Min Max Mean
2014 97 11 10 1 50 120 74.54
2015 73 5 5 0 40 120 78
2016 107 4 4 0 60 170 105
2017 148 7 7 0 65 100 75
2018 153 5 4 1 45 90 72
Total 578 32
min — minimum; max — maximum
Table 5. Data on transurethral resection of bladder tumours (TURBT) broken down by year
Year TURBT Pacemaker Unipolar Bipolar Time
Min Max Mean
2014 448 23 23 0 20 95 54.56
2015 388 17 17 0 35 160 56.17
2016 498 27 26 1 20 130 62.59
2017 452 22 21 1 23 130 59.54
2018 423 25 23 2 35 185 71.2
Total 2,209 114
min — minimum; max — maximum
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problem. A pacemaker-dependent patient is defined as one 
who uses stimulation during more than 40% of evolution 
per day [5, 7, 15]. Therefore, bipolar electrocoagulation is 
preferred, which significantly reduces the risk of pacema-
ker damage. It is also recommended to limit the time of 
electrical applications to 1–2 s for every 10 s of the time 
interval [16, 17]. In the case of bladder tumour electrore-
sections, there are dozens of current applications lasting 
less than 3 s performed. In the case of prostate resections, 
the number of applications is usually much higher, running 
into several hundreds and even more than 1,000.
There are strict recommendations regarding periopera-
tive management in patients with pacemakers [11, 18–21]. 
A patient who is being prepared for the procedure should 
have a current pacemaker control. Expected battery life 
should be at least three months. The procedure for using 
the current application should be described in detail. Du-
ring the procedure, cardiac function should be monitored 
continuously by means of ECG recording and pulse oximetry 
monitoring. Observation after surgery within the hospital 
ward should last a minimum of 24 hours. In the past, it was 
recommended to deactivate the pacemaker during the pro-
cedure when using unipolar electrocoagulation. According 
to the current recommendations of scientific societies in 
the field of electrotherapy, the routine use of a magnet is 
not recommended. It is necessary to provide equipment for 
immediate use when needed i.e. defibrillation, cardiover-
sion and cardiac pacing. Complete damage to a pacemaker 
during surgery is extremely rare. Temporary ineffective 
stimulation or control disorders have been reported. After 
the procedure, early control of the pacing system should 
be conducted. In our study, 146 patients with implanted 
pacemakers did not have damage to the device during or 
after urological procedures. All patients were referred for 
control of pacing systems in the early postoperative period, 
with an average of seven days.
Conclusions
1. Transurethral electroresection of bladder and prostate 
tumours in patients with implanted cardiac pacemakers 
are not associated with complications of the pacemaker 
so long as the principles of management are manta-
ined.
2. Impairment of the pacemaker’s work is extremely rare 
while following rigorous peri-operative recommenda-
tions.
between an atrial and ventricular contraction, which is 
a non-physiological phenomenon.
Since Senning’s first human pacemaker implantation 
in 1958, millions of people have benefited from this tre-
atment. At the same time, progress has also been made 
in the diagnosis and treatment of urological diseases. 
Patients with implanted pacing systems have wider access 
to interventions on the urinary system using current tech-
niques, which can potentially risk damage to the pacing 
system [11].
Transurethral procedures i.e. prostate resection (TURP) 
and bladder tumour resection (TURBT), are very common 
urological procedures [3–5].
Transurethral electroresection (TURP) used in the 
treatment of tumours and prostatic hyperplasia, involves 
the application of a current to the tissues to achieve the 
effect of cutting, coagulation and fulguration to achieve 
haemostasis. In urology, uni- and bi-polar techniques with 
repeated applications of high-intensity current — often 
above 100 V — are used. During the procedure, it is im-
portant to position the so-called passive electrode as far 
away from the cardiac pacing system as possible, e.g. on 
the buttock, which reduces the effect of current on the 
stimulator [12, 13].
During electrocoagulation of both bladder and prostate 
tumours in patients with implanted cardiac pacemakers, 
some authors say that a bipolar technique should be used, 
which significantly reduces the possibility of damage to the 
pacing system. Electrocoagulation is a unipolar configu-
ration that can significantly interfere with the functioning 
of the pacing system by pulses that can be received and 
interpreted as interference, thereby temporarily moving 
the pacemaker to a constant rhythm. The use of electro-
coagulation may block effective stimulation, or temporarily 
suspend the pacemaker’s function. With high coagulation 
current, the endocardium may be damaged at the electro-
de anchor (tissue burn), which is associated with the risk 
of ineffective stimulation [10, 13, 14]. These phenomena 
can be prevented by reprogramming the pacemaker for the 
duration of the procedure, i.e. setting a lower sensitivity, 
or switching to the so-called rigid rhythm, or by setting 
it to trigger mode with a long refractive period. These 
methods were previously the first choice before the advent 
of TURP and TURBT. In a few cases, deactivation of the 
pacemaker (using a magnet) has been used. However, 
in pacemaker-dependent patients, even a short-term 
pacemaker pause can cause a serious haemodynamic 
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Streszczenie
Dokonano analizy przebiegu operacji u 146 pacjentów ze stymulatorami serca, którzy przebyli operacje przezcewkowe 
resekcji gruczołu krokowego i resekcji guzów pęcherza moczowego w klinice urologii w latach 2014–2018. W badanej 
grupie znieczulenie podpajęczynówkowe wykonano u 48 pacjentów (32,9%), a ogólne — u 98 (67,1%). Średni czas trwa-
nia zabiegu wynosił 71,8 minuty. Zabiegi elektroresekcji bipolarnej wykonano u 6 pacjentów, a elektresekcji monopolar-
nej — u 140. W czasie zabiegów stosowano monitorowanie elektrokardiograficzne (EKG) oraz ocenę pulsoksymetryczną 
w sposób ciągły oraz do 4 godzin po zabiegu, 12-odprowadzeniowe EKG spoczynkowe wykonywano przed zabiegiem 
oraz bezpośrednio po nim. U każdego pacjenta kontrolowano pracę stymulatora przed zabiegiem oraz po nim w pracow-
ni kontroli stymulatorów. W żadnym przypadku nie obserwowano istotnych zaburzeń pracy rozrusznika serca. Zabiegi 
przezcewkowej elektroresekcji guzów pęcherza moczowego i prostaty u pacjentów z wszczepionymi stymulatorami serca 
przy zachowaniu zasad postępowania nie wiązały się z wystąpieniem powikłań pracy stymulatora.
Słowa kluczowe: rozrusznik serca, zabiegi przezcewkowe, TURP, TURBT
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